Findings from the National Birth Defects Prevention Study: Interpretation and translation for the clinician

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 103, Issue 8, 2015, Pages 721-728

  Alwan, Sura ^a   Chambers, Christina D ^b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Birth defects; Case control study; Communication of risk; Pregnancy and lactation labeling rule

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; NITROFURANTOIN; OPIATE; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE;

ARTICLE; CASE CONTROL STUDY; CAUSAL ATTRIBUTION; CLINICAL PRACTICE; CLUBFOOT; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DATA ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FERTILIZATION IN VITRO; GASTROSCHISIS; HEREDITY; HUMAN; HYPOTHESIS; INFERTILITY THERAPY; INTERPERSONAL COMMUNICATION; INTRACYTOPLASMIC SPERM INJECTION; MATERNAL CARE; MATERNAL OBESITY; NEURAL TUBE DEFECT; OMPHALOCELE; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPINAL DYSRAPHISM; TERATOGENICITY; UNITED STATES; URINARY TRACT INFECTION; ADVERSE EFFECTS; CONGENITAL ABNORMALITIES; FEMALE; GENETIC PREDISPOSITION; HEALTH SURVEY; MATERNAL EXPOSURE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE;

CASE-CONTROL STUDIES; CONGENITAL ABNORMALITIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MATERNAL EXPOSURE; PHYSICIAN'S ROLE; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84939254568     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23394     Document Type: Article

References (85)

1. Adamson GD, de Mouzon J, Lancaster P, et al. 2006. World collaborative report on in vitro fertilization, 2000. Fertil Steril 85:1586-1622.
2. Ailes EC, Dawson AL, Lind JN, et al. 2015. Opioid prescription claims among women of reproductive age - United States, 2008-2012. MMWR Morb Mortal Wkly Rep 64:37-41.
3. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM. 2011. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 51:264-270.
4. Alwan S, Reefhuis J, Rasmussen SA, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692.
5. American College of Obstetricians and Gynecologists. 2011. Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol 117:1484-1485.
6. American College of Obstetricians and Gynecologists. 2013. Committee Opinion: Obesity in Pregnancy. Number 549.
7. Anderson JL, Waller DK, Canfield MA, et al. 2005. Maternal obesity, gestational diabetes, and central nervous system birth defects. Epidemiology 16:87-92.
8. Andrade SE, Gurwitz JH, Davis RL, et al. 2004. Prescription drug use in pregnancy. American journal of obstetrics and gynecology 191:398-407.
9. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. 2010. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 88:94-100.
10. Berard A, Zhao JP, Sheehy O. 2015. Sertraline use during pregnancy and the risk of major malformations. Am J Obstet Gynecol doi:10.1016/j.ajog.
11. Bracken MB. 1986. Drug use in pregnancy and congenital heart disease in offspring. N Engl J Med 314:1120.
12. Bracken MB, Holford TR. 1981. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 58:336-344.
13. Broussard CS, Rasmussen SA, Reefhuis J, et al. 2011. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 204:314 e311-311.
14. Cai GJ, Sun XX, Zhang L, Hong Q. 2014. Association between maternal body mass index and congenital heart defects in offspring: a systematic review. Am J Obstet Gynecol 211:91-117.
15. Campbell CI, Weisner C, Leresche L, et al. 2010. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health 100:2541-2547.
16. Carmichael SL, Shaw GM, Selvin S, Schaffer DM. 2003. Diet quality and risk of neural tube defects. Med Hypotheses 60:351-355.
17. Cedergren M, Kallen B. 2005. Maternal obesity and the risk for orofacial clefts in the offspring. Cleft Palate Craniofac J 42:367-371.
18. Centre for Maternal and Child Enquires (CMACE). 2010. Maternal obesity in the UK: findings from a national project. Londan: CMACE.
19. Cole JA, Ephross SA, Cosmatos IS, Walker AM. 2007. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16:1075-1085.
20. Conover EA, Polifka JE. 2011. The art and science of teratogen risk communication. Am J Med Genet C Semin Med Genet 157C:227-233.
21. Crider KS, Cleves MA, Reefhuis J, et al. 2009. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 163:978-985.
22. Czeizel AE, Puho E, Sorensen HT, Olsen J. 2004. Possible association between different congenital abnormalities and use of different sulfonamides during pregnancy. Congenit Anom (Kyoto) 44:79-86.
23. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. 2001a. Nitrofurantoin and congenital abnormalities. Eur J Obstet Gynecol Reprod Biol 95:119-126.
24. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. 2001b. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol 15:637-646.
25. Davies MJ, Moore VM, Willson KJ, et al. 2012. Reproductive technologies and the risk of birth defects. N Engl J Med 366:1803-1813.
26. El-Chaar D, Yang Q, Gao J, et al. 2009. Risk of birth defects increased in pregnancies conceived by assisted human reproduction. Fertil Steril 92:1557-1561.
27. Epstein RA, Bobo WV, Martin PR, et al. 2013. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol 23:498-503.
28. Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241.
29. Food Drug Administration. 2014. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist 79:72063-72103.
30. Garcia-Patterson A, Erdozain L, Ginovart G, et al. 2004. In human gestational diabetes mellitus congenital malformations are related to pre-pregnancy body mass index and to severity of diabetes. Diabetologia 47:509-514.
31. Gilboa SM, Correa A, Botto LD, et al. 2010. Association between prepregnancy body mass index and congenital heart defects. Am J Obstet Gynecol 202:51 e51-51 e10.
32. Gu Q, Dillon CF, Burt VL. 2010. Prescription drug use continues to increase: U.S. Prescription Drug Data for 2007-2008. NCHS Data Brief, No. 42. (DHHS Publication No. [PHS] 2010-1209). http://www.cdc.gov/nchs/data/databriefs/db42.pdf.
33. Hailey FJ, Fort H, Williams JC, Hammers B. 1983. Foetal safety of nitrofurantoin macrocrystals therapy during pregnancy: a retrospective analysis. J Int Med Res 11:364-369.
34. Hansen M, Bower C, Milne E, et al. 2005. Assisted reproductive technologies and the risk of birth defects-a systematic review. Hum Reprod 20:328-338.
35. Hendricks KA, Nuno OM, Suarez L, Larsen R. 2001. Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans. Epidemiology 12:630-635.
36. Huybrechts KF, Palmsten K, Avorn J, et al. 2014. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370:2397-2407.
37. Jimenez-Solem E, Andersen JT, Petersen M, et al. 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2:pii:e001148.
38. Jovanovic-Peterson L, Peterson CM. 1993. Abnormal metabolism and the risk for birth defects with emphasis on diabetes. Ann N Y Acad Sci 678:228-243.
39. Kallen B, Finnstrom O, Nygren KG, Olausson PO. 2005. In vitro fertilization (IVF) in Sweden: risk for congenital malformations after different IVF methods. Birth Defects Res A Clin Mol Teratol 73:162-169.
40. Kallen B, Otterblad Olausson P. 2006. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 21:221-222.
41. Kallen BA, Otterblad Olausson P. 2003. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17:255-261.
42. Kellogg A, Rose CH, Harms RH, Watson WJ. 2011. Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol 204:259 e251-254.
43. Kornum JB, Nielsen RB, Pedersen L, et al. 2010. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2:29-36.
44. Leguizamon G, Igarzabal ML, Reece EA. 2007. Periconceptional care of women with diabetes mellitus. Obstet Gynecol Clin North Am 34:225-239, viii.
45. Lie RT, Lyngstadaas A, Orstavik KH, et al. 2005. Birth defects in children conceived by ICSI compared with children conceived by other IVF-methods; a meta-analysis. Int J Epidemiol 34:696-701.
46. Louik C, Lin AE, Werler MM, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683.
47. Macintosh MC, Fleming KM, Bailey JA, et al. 2006. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 333:177.
48. Malm H, Artama M, Gissler M, Ritvanen A. 2011. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 118:111-120.
49. Margulis AV, Abou-Ali A, Strazzeri MM, et al. 2013. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD. Pharmacoepidemiol Drug Saf 22:942-951.
50. Merlob P, Birk E, Sirota L, et al. 2009. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 85:837-841.
51. Meunier MR, Bennett IM, Coco AS. 2013. Use of antidepressant medication in the United States during pregnancy, 2002-2010. Psychiatr Serv 64:1157-1160.
52. Mills JL, Troendle J, Conley MR, et al. 2010. Maternal obesity and congenital heart defects: a population-based study. Am J Clin Nutr 91:1543-1549.
53. Mitchell AA. 2012. Studies of drug-induced birth defects. In: Strom B, Kimmel S, Hennessy S, editors. Pharmacoepidemiology. 5th ed. West Sussex, UK: Wiley-Blackwell. pp. 487-504.
54. Mitchell AA, Gilboa SM, Werler MM, et al. 2011. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 205:51 e51-e58.
55. Munoz MA, Stojanovic D, Etminan M, et al. 2012. Trends in use of of benzodiazepines, opioids, tramadol, and Z-drugs from 1998 to 2008 in a managed care population. Pharmacoepidemiol Drug Saf 21(Suppl 3):426.
56. Must A, Spadano J, Coakley EH, et al. 1999. The disease burden associated with overweight and obesity. JAMA 282:1523-1529.
57. Narayan KM, Boyle JP, Thompson TJ, et al. 2007. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care 30:1562-1566.
58. Oberlander TF, Warburton W, Misri S, et al. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B 83:68-76.
59. Olson CK, Keppler-Noreuil KM, Romitti PA, et al. 2005. In vitro fertilization is associated with an increase in major birth defects. Fertil Steril 84:1308-1315.
60. Pedersen LH, Henriksen TB, Vestergaard M, et al. 2009. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339:b3569.
61. Polonsky KS, Sturis J, Bell GI. 1996. Seminars in medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334:777-783.
62. Rasmussen SA, Chu SY, Kim SY, et al. 2008. Maternal obesity and risk of neural tube defects: a metaanalysis. Am J Obstet Gynecol 198:611-619.
63. Reefhuis J, Honein MA, Schieve LA, et al. 2009. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod 24:360-366.
64. Reis M, Kallen B. 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40:1723-1733.
65. Romundstad LB, Romundstad PR, Sunde A, et al. 2008. Effects of technology or maternal factors on perinatal outcome after assisted fertilisation: a population-based cohort study. Lancet 372:737-743.
66. Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. 1979. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 109:433-439.
67. Ryan D, Milis L, Misri N. 2005. Depression during pregnancy. Can Fam Physician 51:1087-1093.
68. Saxen I. 1975. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 4:37-44.
69. Scialli AR. 2006. Teratology Public Affairs Committee position paper: maternal obesity and pregnancy. Birth Defects Res A Clin Mol Teratol 76:73-77.
70. Seggers J, de Walle HE, Bergman JE, et al. 2015. Congenital anomalies in offspring of subfertile couples: a registry-based study in the northern Netherlands. Fertil Steril 103:1001-1010.
71. Shaw GM, Todoroff K, Schaffer DM, Selvin S. 2000. Maternal height and prepregnancy body mass index as risk factors for selected congenital anomalies. Paediatr Perinat Epidemiol 14:234-239.
72. Shaw GM, Velie EM, Schaffer D. 1996. Risk of neural tube defect-affected pregnancies among obese women. JAMA 275:1093-1096.
73. Stothard KJ, Tennant PW, Bell R, Rankin J. 2009. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 301:636-650.
74. Tinker SC, Gibbs C, Strickland MJ, et al. 2013. Impact of time to maternal interview on interview responses in the National Birth Defects Prevention Study. Am J Epidemiol 177:1225-1235.
75. Waller DK, Shaw GM, Rasmussen SA, et al. 2007. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 161:745-750.
76. Watkins ML, Scanlon KS, Mulinare J, Khoury MJ. 1996. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology 7:507-512.
77. Wen J, Jiang J, Ding C, et al. 2012. Birth defects in children conceived by in vitro fertilization and intracytoplasmic sperm injection: a meta-analysis. Fertil Steril 97:1331-1337 e1331-1334.
78. Werler MM, Louik C, Shapiro S, Mitchell AA. 1996. Prepregnant weight in relation to risk of neural tube defects. JAMA 275:1089-1092.
79. Wisner KL, Gelenberg AJ, Leonard H, et al. 1999. Pharmacologic treatment of depression during pregnancy. JAMA 282:1264-1269.
80. Wogelius P, Norgaard M, Gislum M, et al. 2006. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17:701-704.
81. Wurst KE, Poole C, Ephross SA, Olshan AF. 2010. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 88:159-170.
82. Yazdy MM, Mitchell AA, Tinker SC, et al. 2013. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol 122:838-844.
83. Yoon PW, Rasmussen SA, Lynberg MC, et al. 2001. The National Birth Defects Prevention Study. Public Health Rep 116(Suppl 1):32-40.
84. Zhu JL, Basso O, Obel C, et al. 2006. Infertility, infertility treatment, and congenital malformations: Danish national birth cohort. BMJ 333:679.
85. Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 313:347-352.